Cargando…

Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis

Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are commonly encountered diseases in males. Studies showed that genetic factors are responsible for the occurrences of both diseases. However, the genetic association between them is still unclear. Gene Expression Omnibus (GEO) database can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xi, Ma, Junjie, Xu, Chengdang, Wang, Licheng, Yao, Yicong, Wang, Xinan, Zi, Tong, Bian, Cuidong, Wu, Denglong, Wu, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243208/ https://www.ncbi.nlm.nih.gov/pubmed/35768705 http://dx.doi.org/10.1007/s12672-022-00508-y

Ejemplares similares

Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
por: Wang, Licheng, et al.
Publicado: (2021)

Identification of cuproptosis-related genes for predicting the development of prostate cancer
por: Wang, Xin’an, et al.
Publicado: (2023)

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
por: Chen, Xi, et al.
Publicado: (2022)

MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer
por: Xiang, Jun, et al.
Publicado: (2015)

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression
por: Hong, Zhe, et al.
Publicado: (2023)

Benign Prostatic Hyperplasia
Publicado: (2015)

Expression and Localization of Aquaporins in Benign Prostate Hyperplasia and Prostate Cancer
por: Hwang, Insang, et al.
Publicado: (2012)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer
por: Ratajczak, Weronika, et al.
Publicado: (2022)

Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer
por: Glaser, Alexander, et al.
Publicado: (2022)

Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients
por: Kim, Sung Han, et al.
Publicado: (2021)

Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer
por: Wu, Wei, et al.
Publicado: (2023)

Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer
por: Sarkar, Purandar, et al.
Publicado: (2022)

Fibronectin Pattern in Benign Hyperplasia and Cancer of the Prostate
por: Janković, Miroslava M., et al.
Publicado: (2008)

Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis
por: Zhang, Lei, et al.
Publicado: (2020)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts
por: Prajapati, Akhilesh, et al.
Publicado: (2013)

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
por: Hsiao, Chun-Jen, et al.
Publicado: (2016)

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer
por: Oseni, Saheed Oluwasina, et al.
Publicado: (2023)

Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia
por: Jin, Wei, et al.
Publicado: (2020)

Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer
por: Hillebrand, Ana Caroline, et al.
Publicado: (2018)

Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
por: Yang, Che-Hsueh, et al.
Publicado: (2022)

Biexponential Apparent Diffusion Coefficients Values in the Prostate: Comparison among Normal Tissue, Prostate Cancer, Benign Prostatic Hyperplasia and Prostatitis
por: Liu, Xiaohang, et al.
Publicado: (2013)

Prostate and renal cancer, benign prostatic hyperplasia, erectile dysfunction and basic research : an update
Publicado: (2003)

Benign prostatic hyperplasia and subsequent risk of bladder cancer
por: Kang, D, et al.
Publicado: (2007)

Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia
por: Huang, Jin, et al.
Publicado: (2015)

Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma
por: Christudoss, Pamela, et al.
Publicado: (2011)

Rare Variant of Carcinoma Prostate Masquerading as Benign Prostatic Hyperplasia
por: Khanduri, Sachin, et al.
Publicado: (2019)

Prostate sarcomas: A radiological mimic for benign prostatic hyperplasia
por: Whish-Wilson, Thomas, et al.
Publicado: (2020)

Prostate embolization in the treatment of benign prostatic hyperplasia: what’s the point?
por: Nunes, Thiago Franchi, et al.
Publicado: (2021)

Prostate cancer identification via photoacoustic spectroscopy and machine learning
por: Chen, Yingna, et al.
Publicado: (2021)

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
por: Cohen, P., et al.
Publicado: (1998)

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
por: Mantzoros, C. S., et al.
Publicado: (1997)

Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer
por: Jedinak, Andrej, et al.
Publicado: (2015)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gfrj4teuj09j5oabf4ivdn3t65